A state-of-the-art lecture titled “Myeloproliferative Neoplasm-associated Thrombosis” was presented at the ISTH congress in 2021. We summarize here the main points of the lecture with two purposes: to report the incidence rates of major thrombosis in polycythemia vera and essential thrombocythemia and to discuss to what extent cytoreductive therapy and antithrombotic drugs have reduced the incidence of these events. Unfortunately, the incidence rate of thrombosis remains high, ranging between 2 and 5/100 person-years. It is likely that new drugs such as interferon and ruxolitinib can be more efficacious given their cytoreductive and anti-inflammatory activities. Despite prophylaxis with vitamin K antagonists and direct oral anticoagulants after venous thrombosis in either common sites or splanchnic or cerebral sites, the incidence rate is still elevated, as high as 4 to 5/100 person-years. Future studies with new drugs or new strategies should consider thrombosis as the primary endpoint or surrogate biomarkers only if previously validated.

Barbui, T., Carobbio, A., De Stefano, V., Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment, <<RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS>>, 2022; 6 (1): e12657-N/A. [doi:10.1002/rth2.12657] [http://hdl.handle.net/10807/202978]

Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment

De Stefano, V.
2022

Abstract

A state-of-the-art lecture titled “Myeloproliferative Neoplasm-associated Thrombosis” was presented at the ISTH congress in 2021. We summarize here the main points of the lecture with two purposes: to report the incidence rates of major thrombosis in polycythemia vera and essential thrombocythemia and to discuss to what extent cytoreductive therapy and antithrombotic drugs have reduced the incidence of these events. Unfortunately, the incidence rate of thrombosis remains high, ranging between 2 and 5/100 person-years. It is likely that new drugs such as interferon and ruxolitinib can be more efficacious given their cytoreductive and anti-inflammatory activities. Despite prophylaxis with vitamin K antagonists and direct oral anticoagulants after venous thrombosis in either common sites or splanchnic or cerebral sites, the incidence rate is still elevated, as high as 4 to 5/100 person-years. Future studies with new drugs or new strategies should consider thrombosis as the primary endpoint or surrogate biomarkers only if previously validated.
2022
Inglese
Barbui, T., Carobbio, A., De Stefano, V., Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment, <<RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS>>, 2022; 6 (1): e12657-N/A. [doi:10.1002/rth2.12657] [http://hdl.handle.net/10807/202978]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/202978
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 18
social impact